ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Dr. Reddy's Laboratories tries to cure US regulatory woes

MUMBAI -- Stiffer competition and launch delays following warning letters from the U.S. Food and Drug Administration (FDA) pulled down earnings for Dr. Reddy's Laboratories in the first quarter of its financial year, which began in April.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more